Figure 2.

Comparison of mortality rates and the average APACHE II score in the subgroup of patients receiving rhAPC with APACHE II scores ≥ 25 from the PROWESS trial to mortality rates and average APACHE II scores in patients receiving rhAPC in subsequent uncontrolled trials. Mortality rates at 28 days are shown in the upper panel A) and at hospital or intensive care unit discharge or 90 days in the lower panel B). results from the subgroup of patients shown from the PROWESS trial provided the basis for approval of rhAPC. in almost all uncontrolled studies, mortality rates have been higher and average APACHE II scores lower than in the subgroup in PROWESS with APACHE II ≥ 25.

Notes: ^aNA, Not available; ^bICU mortality; ^cInterquartile range; ^d90-day mortality.